News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kythera Biopharmaceuticals Receives Notice of Allowance from U.S. Patent Office for Composition Claims Covering ATX-101 Active Ingredient


6/1/2012 9:46:08 AM

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable “double chin.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES